AEON Biopharma (AEON) Liabilities and Shareholders Equity (2020 - 2026)

AEON Biopharma has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $5.6 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 76.96% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $39.8 million (up 149.84% YoY) and the FY2025 annual result came in at $5.6 million, up 76.96% from the prior year.
• Liabilities and Shareholders Equity fell to $5.6 million in Q4 2025 per AEON's latest filing, from $8.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $278.1 million in Q1 2021 and troughed at $3.0 million in Q1 2024.
• A 5-year average of $103.7 million and a median of $15.7 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2021 and 2022: Liabilities and Shareholders Equity surged 341813.0% in 2021, then slumped 96.11% in 2022.
• Over 5 years, Liabilities and Shareholders Equity stood at $276.9 million in 2021, then plunged by 96.11% to $10.8 million in 2022, then sank by 36.49% to $6.8 million in 2023, then tumbled by 54.1% to $3.1 million in 2024, then surged by 76.96% to $5.6 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $5.6 million, $8.7 million, and $11.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.